Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients

Hirokazu Matsushita, Akiko Uenaka, Toshiro Ono, Kosei Hasegawa, Shuichiro Sato, Fumihito Koizumi, Kazuhiko Nakagawa, Masahiro Toda, Tetsuro Shingo, Tomotsugu Ichikawa, Yuji Noguchi, Takashi Tamiya, Tomohisa Furuta, Takeshi Kawase, Isao Date, Eiichi Nakayama

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

For regulatory factor X4 (RFX4), two alternatively spliced variants, RFX4-A and -B, were reported in the testis. In this study, we identified transcript variants RFX4-C, -D, -E, and -F, and demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) that RFX4-A, -B and -C mRNAs were expressed only in the testis, and RFX4-D mRNA was expressed only in normal brain tissues. In tumors, RFX4-E and -F in addition to RFX4-D mRNA were expressed in gliomas by rapid amplification of cDNA ends and RT-PCR analyses. Expression of RFX4 mRNA was not observed in other tumors, such as lung, esophageal, stomach, colon or liver cancers. Quantitative real-time RT-PCR using common primer pairs detecting all of the variant transcripts showed high expression in normal testis, low expression in the brain (1% compared to the expression in testis), and overexpression in 17 of 61 gliomas (28%). Western blot analysis using DC28 monoclonal antibody (mAb) produced against recombinant RFX4-D C-terminus protein showed expression of RFX4-A and -C proteins, but not RFX4-B protein, in the testis, and expression of RFX4-D protein in the brain. Moreover, expression of RFX4-E and -F proteins, but not RFX4-D protein, was observed in gliomas. Immunohistochemistry analysis using DC28 mAb showed positive staining in the nuclei of spermatocytes in the testis and glioma cells. Antibody against RFX4 was detected in the sera of 3 of 58 (5%) glioma patients by enzyme-linked immunosorbent assay, suggesting the immunogenicity of RFX4-E and -F proteins in glioma patients.

Original languageEnglish
Pages (from-to)801-809
Number of pages9
JournalCancer Science
Volume96
Issue number11
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Humoral Immunity
Glioma
Testis
Protein Isoforms
Reverse Transcription
Messenger RNA
Proteins
Polymerase Chain Reaction
Brain
Monoclonal Antibodies
Dilatation and Curettage
Spermatocytes
Liver Neoplasms
Esophageal Neoplasms
Protein C
Colonic Neoplasms
Stomach Neoplasms
Lung Neoplasms
Neoplasms
Complementary DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients. / Matsushita, Hirokazu; Uenaka, Akiko; Ono, Toshiro; Hasegawa, Kosei; Sato, Shuichiro; Koizumi, Fumihito; Nakagawa, Kazuhiko; Toda, Masahiro; Shingo, Tetsuro; Ichikawa, Tomotsugu; Noguchi, Yuji; Tamiya, Takashi; Furuta, Tomohisa; Kawase, Takeshi; Date, Isao; Nakayama, Eiichi.

In: Cancer Science, Vol. 96, No. 11, 11.2005, p. 801-809.

Research output: Contribution to journalArticle

Matsushita, H, Uenaka, A, Ono, T, Hasegawa, K, Sato, S, Koizumi, F, Nakagawa, K, Toda, M, Shingo, T, Ichikawa, T, Noguchi, Y, Tamiya, T, Furuta, T, Kawase, T, Date, I & Nakayama, E 2005, 'Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients', Cancer Science, vol. 96, no. 11, pp. 801-809. https://doi.org/10.1111/j.1349-7006.2005.00112.x
Matsushita, Hirokazu ; Uenaka, Akiko ; Ono, Toshiro ; Hasegawa, Kosei ; Sato, Shuichiro ; Koizumi, Fumihito ; Nakagawa, Kazuhiko ; Toda, Masahiro ; Shingo, Tetsuro ; Ichikawa, Tomotsugu ; Noguchi, Yuji ; Tamiya, Takashi ; Furuta, Tomohisa ; Kawase, Takeshi ; Date, Isao ; Nakayama, Eiichi. / Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients. In: Cancer Science. 2005 ; Vol. 96, No. 11. pp. 801-809.
@article{6d1b5a866cfd4860a847f4c130897ac1,
title = "Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients",
abstract = "For regulatory factor X4 (RFX4), two alternatively spliced variants, RFX4-A and -B, were reported in the testis. In this study, we identified transcript variants RFX4-C, -D, -E, and -F, and demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) that RFX4-A, -B and -C mRNAs were expressed only in the testis, and RFX4-D mRNA was expressed only in normal brain tissues. In tumors, RFX4-E and -F in addition to RFX4-D mRNA were expressed in gliomas by rapid amplification of cDNA ends and RT-PCR analyses. Expression of RFX4 mRNA was not observed in other tumors, such as lung, esophageal, stomach, colon or liver cancers. Quantitative real-time RT-PCR using common primer pairs detecting all of the variant transcripts showed high expression in normal testis, low expression in the brain (1{\%} compared to the expression in testis), and overexpression in 17 of 61 gliomas (28{\%}). Western blot analysis using DC28 monoclonal antibody (mAb) produced against recombinant RFX4-D C-terminus protein showed expression of RFX4-A and -C proteins, but not RFX4-B protein, in the testis, and expression of RFX4-D protein in the brain. Moreover, expression of RFX4-E and -F proteins, but not RFX4-D protein, was observed in gliomas. Immunohistochemistry analysis using DC28 mAb showed positive staining in the nuclei of spermatocytes in the testis and glioma cells. Antibody against RFX4 was detected in the sera of 3 of 58 (5{\%}) glioma patients by enzyme-linked immunosorbent assay, suggesting the immunogenicity of RFX4-E and -F proteins in glioma patients.",
author = "Hirokazu Matsushita and Akiko Uenaka and Toshiro Ono and Kosei Hasegawa and Shuichiro Sato and Fumihito Koizumi and Kazuhiko Nakagawa and Masahiro Toda and Tetsuro Shingo and Tomotsugu Ichikawa and Yuji Noguchi and Takashi Tamiya and Tomohisa Furuta and Takeshi Kawase and Isao Date and Eiichi Nakayama",
year = "2005",
month = "11",
doi = "10.1111/j.1349-7006.2005.00112.x",
language = "English",
volume = "96",
pages = "801--809",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients

AU - Matsushita, Hirokazu

AU - Uenaka, Akiko

AU - Ono, Toshiro

AU - Hasegawa, Kosei

AU - Sato, Shuichiro

AU - Koizumi, Fumihito

AU - Nakagawa, Kazuhiko

AU - Toda, Masahiro

AU - Shingo, Tetsuro

AU - Ichikawa, Tomotsugu

AU - Noguchi, Yuji

AU - Tamiya, Takashi

AU - Furuta, Tomohisa

AU - Kawase, Takeshi

AU - Date, Isao

AU - Nakayama, Eiichi

PY - 2005/11

Y1 - 2005/11

N2 - For regulatory factor X4 (RFX4), two alternatively spliced variants, RFX4-A and -B, were reported in the testis. In this study, we identified transcript variants RFX4-C, -D, -E, and -F, and demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) that RFX4-A, -B and -C mRNAs were expressed only in the testis, and RFX4-D mRNA was expressed only in normal brain tissues. In tumors, RFX4-E and -F in addition to RFX4-D mRNA were expressed in gliomas by rapid amplification of cDNA ends and RT-PCR analyses. Expression of RFX4 mRNA was not observed in other tumors, such as lung, esophageal, stomach, colon or liver cancers. Quantitative real-time RT-PCR using common primer pairs detecting all of the variant transcripts showed high expression in normal testis, low expression in the brain (1% compared to the expression in testis), and overexpression in 17 of 61 gliomas (28%). Western blot analysis using DC28 monoclonal antibody (mAb) produced against recombinant RFX4-D C-terminus protein showed expression of RFX4-A and -C proteins, but not RFX4-B protein, in the testis, and expression of RFX4-D protein in the brain. Moreover, expression of RFX4-E and -F proteins, but not RFX4-D protein, was observed in gliomas. Immunohistochemistry analysis using DC28 mAb showed positive staining in the nuclei of spermatocytes in the testis and glioma cells. Antibody against RFX4 was detected in the sera of 3 of 58 (5%) glioma patients by enzyme-linked immunosorbent assay, suggesting the immunogenicity of RFX4-E and -F proteins in glioma patients.

AB - For regulatory factor X4 (RFX4), two alternatively spliced variants, RFX4-A and -B, were reported in the testis. In this study, we identified transcript variants RFX4-C, -D, -E, and -F, and demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) that RFX4-A, -B and -C mRNAs were expressed only in the testis, and RFX4-D mRNA was expressed only in normal brain tissues. In tumors, RFX4-E and -F in addition to RFX4-D mRNA were expressed in gliomas by rapid amplification of cDNA ends and RT-PCR analyses. Expression of RFX4 mRNA was not observed in other tumors, such as lung, esophageal, stomach, colon or liver cancers. Quantitative real-time RT-PCR using common primer pairs detecting all of the variant transcripts showed high expression in normal testis, low expression in the brain (1% compared to the expression in testis), and overexpression in 17 of 61 gliomas (28%). Western blot analysis using DC28 monoclonal antibody (mAb) produced against recombinant RFX4-D C-terminus protein showed expression of RFX4-A and -C proteins, but not RFX4-B protein, in the testis, and expression of RFX4-D protein in the brain. Moreover, expression of RFX4-E and -F proteins, but not RFX4-D protein, was observed in gliomas. Immunohistochemistry analysis using DC28 mAb showed positive staining in the nuclei of spermatocytes in the testis and glioma cells. Antibody against RFX4 was detected in the sera of 3 of 58 (5%) glioma patients by enzyme-linked immunosorbent assay, suggesting the immunogenicity of RFX4-E and -F proteins in glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=29644439955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29644439955&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2005.00112.x

DO - 10.1111/j.1349-7006.2005.00112.x

M3 - Article

VL - 96

SP - 801

EP - 809

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -